📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 16:06
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
20 announcements match the current filters (relevance ≥ 5).
Kopran Q1 FY27 Revenue Grows 13.9% to ₹154 Cr; Net Profit Dips 10% YoY to ₹6.7 Cr
Kopran Limited reported a 13.9% YoY increase in revenue from operations to ₹153.99 Cr for Q1 FY27. EBITDA grew 11.1% to ₹15.88 Cr, though margins slightly contracted to 10.31% from 10.57% in the year-ago period. Net profit declined by 10% YoY to ₹6.70 Cr, primarily due to higher finance costs (up 29% YoY) and increased depreciation. The API segment remains the dominant contributor at ₹95.38 Cr, while Formulations contributed ₹57.09 Cr with a strong focus on Southeast Asian markets.
Confidence: HIGH
What changedThe filing provides the first detailed operational and segment-wise breakdown for FY27, showing a shift toward domestic API sales and growth in the Southeast Asian formulation market.
Why it mattersIt highlights the company's ongoing struggle to maintain margins despite revenue growth, and its heavy reliance on the API segment (62.5% of revenue) which is subject to raw material price volatility.
Q1 FY27 Revenue: ₹153.99 CrQ1 FY27 Net Profit: ₹6.70 CrAPI Segment Revenue: ₹95.38 CrFormulations Segment Revenue: ₹57.09 CrNet Debt/Equity: 0.30xQ1 Revenue vs TTM Revenue: 22.6%
📅 Short termThe stock may see neutral to slightly cautious movement as the market weighs double-digit revenue growth against declining bottom-line profitability and margin pressure.
📈 Long termLong-term value depends on the successful integration of the API and Formulations verticals and reducing dependence on Chinese raw materials through the Panoli facility.
⚠ Risk flags
- Rising finance costs (₹3.28 Cr in Q1 vs ₹2.54 Cr YoY)
- Margin contraction
- High geographic concentration in Formulations (Africa and SE Asia)
Key Highlights
Revenue from operations rose to ₹153.99 Cr in Q1 FY27 compared to ₹135.22 Cr in Q1 FY26.
API segment revenue reached ₹95.38 Cr, with domestic sales (₹56.77 Cr) significantly higher than exports (₹38.61 Cr).
Formulations revenue stood at ₹57.09 Cr, with Southeast Asia contributing ₹28.46 Cr (approx. 50% of segment sales).
Net Debt-to-Equity ratio increased to 0.30x as of June 2026, up from 0.27x in FY26.
EBITDA margin stood at 10.31%, remaining below the FY25 full-year average of 11.9%.
👀 What to Watch
Investors should monitor the stabilization of EBITDA margins and the execution of the Panoli (Gujarat) API facility expansion. Watch for the impact of the proposed amalgamation of Kopran Laboratories Limited on operational synergies.
Kopran Q1 FY27 Revenue Up 14% YoY to ₹154 Cr; Net Profit Declines 10% to ₹6.7 Cr
Kopran reported a mixed Q1 FY27 with consolidated revenue growing 13.9% YoY to ₹153.99 Cr, but declining sharply by 34.2% on a sequential (QoQ) basis. Net profit followed a similar trend, falling 10.1% YoY to ₹6.70 Cr and dropping 64.5% from the ₹18.87 Cr reported in the previous quarter (Mar 2026). Profitability was impacted by a contraction in PBT margins to 5.7% from 7.3% in the year-ago period, alongside a 29% increase in finance costs. While standalone profit grew YoY, the consolidated performance reflects significant volatility in the business cycle.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, showing year-on-year revenue growth but a significant sequential decline in both revenue and profitability.
Why it mattersThe results highlight margin pressure and high volatility in the company's consolidated performance, which is critical for a small-cap pharma player with a market cap of ₹917 Cr.
Consolidated Revenue (Q1 FY27): ₹153.99 CrConsolidated Net Profit (Q1 FY27): ₹6.70 CrYoY Revenue Growth: 13.9%QoQ Revenue Growth: -34.2%PBT Margin: 5.7%Basic EPS: ₹1.39
📅 Short termThe stock may face downward pressure in the short term due to the sharp sequential (QoQ) decline in earnings and margin contraction.
📈 Long termLong-term prospects depend on the successful consolidation of operations through the KLL merger and expansion into higher-margin therapeutic segments like anti-diabetics.
⚠ Risk flags
- Sharp sequential earnings volatility
- Margin contraction (PBT margin down to 5.7%)
- Rising finance costs
Key Highlights
Consolidated Revenue from Operations reached ₹153.99 Cr, up 13.9% from ₹135.22 Cr in June 2025.
Consolidated Net Profit fell to ₹6.70 Cr, a 10.1% decline compared to ₹7.45 Cr in the same quarter last year.
Sequential revenue witnessed a sharp 34.2% drop from ₹234.02 Cr in the March 2026 quarter.
Finance costs rose to ₹3.28 Cr from ₹2.54 Cr YoY, representing a 29.3% increase.
Inventory changes showed a significant build-up of ₹33.93 Cr (negative adjustment) compared to a ₹4.71 Cr build-up in June 2025.
👀 What to Watch
Monitor the stabilization of operating margins and the progress of the pending amalgamation of Kopran Laboratories Limited (KLL). Investors should watch for management commentary on the sharp sequential revenue drop to determine if it is seasonal or a structural demand issue in the API segment.
Kopran Appoints Pharma Veteran Vijay L Thange as Chief Technical Officer
Kopran Limited has announced the appointment of Mr. Vijay L Thange as Chief Technical Officer (CTO) effective June 26, 2026. Mr. Thange is a seasoned professional with over 36 years of experience in the pharmaceutical industry, having worked with reputable firms like Cipla and RPG Life Sciences. Most recently, he served as Vice President of Plant Operations at USV Limited, bringing significant technical and operational expertise to Kopran. This appointment is expected to bolster the company's manufacturing capabilities and technical oversight.
Key Highlights
Mr. Vijay L Thange appointed as Chief Technical Officer effective June 26, 2026.
Brings over 36 years of extensive experience in the pharmaceutical sector.
Previously served as Vice President of Plant Operations at USV Limited.
Educational qualifications include BSc, LLB, PGD (Operation), and an MBA in Operations Management.
👀 What to Watch
This is a positive management update; investors should monitor if this veteran leadership leads to improved manufacturing efficiencies or regulatory compliance.
Kopran Shareholders and Creditors Approve Merger with Kopran Laboratories with 99.95% Majority
Kopran Limited shareholders and creditors have overwhelmingly approved the Scheme of Amalgamation with Kopran Laboratories Limited (KLL) in an NCLT-convened meeting held on June 3, 2026. The resolution received 99.95% of total votes in favor, with 100% support from both promoters and institutional investors. This merger aims to consolidate operations and simplify the corporate structure, and it has now cleared a major hurdle toward final implementation. The company will now proceed with the final stages of NCLT approval to conclude the transaction.
Key Highlights
Shareholders approved the merger of Kopran Laboratories Limited (Transferor) into Kopran Limited (Transferee) with a 99.95% majority.
Promoter and Promoter Group cast 21,449,203 votes, representing 100% support for the resolution.
Public Institutional investors also voted 100% in favor, while Public Non-Institutional support stood at 98.98%.
The meeting was convened following an NCLT Mumbai Bench order dated April 09, 2026, and conducted via Video Conferencing.
The resolution was passed as a Special Resolution, fulfilling the requisite majority requirements for the scheme.
👀 What to Watch
Investors should maintain a positive outlook as the high approval rate minimizes the risk of shareholder litigation; monitor for the final NCLT sanction and the subsequent impact on consolidated earnings.
Kopran Q4 FY26 Revenue Surges 36% to ₹234 Cr; EBITDA Margins Double to 17.3%
Kopran Limited reported a robust Q4 FY26 with revenue of ₹234.02 crore and its highest-ever quarterly EBITDA of ₹40.57 crore. Despite a 7.5% growth in annual revenue to ₹681.42 crore, full-year net profit declined to ₹25.73 crore from ₹38.55 crore in FY25 due to increased depreciation and finance costs. The API vertical remains the primary driver, contributing 55% of total revenue. A significant corporate action is pending with the NCLT-directed meeting for the merger of Kopran Laboratories scheduled for June 2026.
Key Highlights
Q4 FY26 Revenue rose 35.8% YoY to ₹23,402 Lakhs with EBITDA margins expanding to 17.34% from 8.12%.
Full-year FY26 revenue stood at ₹68,142 Lakhs, marking a steady growth from ₹63,359 Lakhs in FY25.
API segment revenue for FY26 was ₹37,335 Lakhs, while Formulations contributed ₹29,639 Lakhs.
Net Profit for FY26 decreased to ₹2,573 Lakhs compared to ₹3,855 Lakhs in the previous fiscal year.
NCLT meeting for the merger with Kopran Laboratories Limited is scheduled for June 3, 2026.
👀 What to Watch
The sharp recovery in Q4 margins is a positive signal; however, investors should track the impact of the upcoming merger on the consolidated balance sheet. Focus on the API segment's growth and the company's ability to maintain the improved Q4 margin profile.
Kopran Q4 Net Profit Jumps 95% YoY to ₹18.87 Cr; Recommends ₹3 Dividend
Kopran Limited reported a robust performance for Q4 FY26, with consolidated revenue growing 35.8% YoY to ₹234.02 crore. Net profit for the quarter surged nearly 95% to ₹18.87 crore compared to ₹9.68 crore in the same period last year. Despite the strong quarterly finish, full-year FY26 consolidated profit declined to ₹25.73 crore from ₹38.55 crore in FY25. The board has recommended a dividend of ₹3 per share (30%) and provided an update on the pending merger with Kopran Laboratories, scheduled for a shareholder vote in June 2026.
Key Highlights
Consolidated Q4 Revenue increased 35.8% YoY to ₹234.02 crore from ₹172.36 crore.
Quarterly Net Profit rose 94.9% YoY to ₹18.87 crore.
Recommended a final dividend of ₹3.00 per equity share for FY25-26.
Full-year FY26 consolidated revenue reached ₹681.42 crore, up from ₹629.60 crore in FY25.
NCLT-directed meeting for the merger with Kopran Laboratories is set for June 3, 2026.
👀 What to Watch
The strong Q4 recovery suggests operational momentum; investors should monitor the outcome of the June 3rd NCLT meeting regarding the merger as a key catalyst. The ₹3 dividend provides a decent yield for long-term holders.
Kopran Subsidiary KRLL to Raise ₹18.75 Cr via Rights Issue; Appoints New Independent Director
Kopran Limited's subsidiary, Kopran Research Laboratories Limited (KRLL), has approved a rights issue to raise ₹18.75 crores to meet its working capital requirements. The rights issue is structured at a ratio of 1 share for every 12 held, priced at ₹100 per share (including a ₹90 premium). Additionally, the company has appointed Mr. Chandresh Gandhi, a veteran Chartered Accountant with over 30 years of experience, as an Independent Director for a five-year term. This move aims to strengthen both the subsidiary's balance sheet and its corporate governance.
Key Highlights
Subsidiary KRLL to raise ₹18.75 crores through a Rights Issue for working capital needs
Rights Issue ratio set at 1 share for every 12 shares held at a price of ₹100 per share
Appointment of Mr. Chandresh Gandhi as Independent Director for a 5-year term starting May 18, 2026
Mr. Gandhi brings 30+ years of expertise in auditing, international taxation, and FEMA compliance
The fundraise is intended to improve the operational liquidity of the research-focused subsidiary
👀 What to Watch
Investors should view the capital infusion into the subsidiary as a positive step for operational growth, while monitoring how the improved liquidity impacts Kopran's consolidated earnings.
Kopran Subsidiary KRLL to Raise ₹18.75 Cr via Rights Issue; Appoints New Director
Kopran Limited's subsidiary, Kopran Research Laboratories Limited (KRLL), has approved a rights issue to raise ₹18.75 crores to meet its working capital requirements. The issue is priced at ₹100 per share (₹10 face value plus ₹90 premium) with an entitlement ratio of 1 share for every 12 held. Alongside the fundraise, the company has appointed Mr. Chandresh Gandhi, a veteran Chartered Accountant with 30 years of experience, as an Independent Director for a five-year term. These steps are aimed at strengthening both the liquidity and the governance framework of the subsidiary.
Key Highlights
Subsidiary KRLL to raise ₹18.75 crores through a rights issue for working capital
Rights issue ratio set at 1 share for every 12 shares held at a price of ₹100 per share
Appointment of Mr. Chandresh Gandhi as Independent Director for a 5-year term starting May 18, 2026
Mr. Gandhi brings over 30 years of expertise in auditing, international taxation, and FEMA compliance
👀 What to Watch
Investors should view this as a positive step for the subsidiary's operational liquidity. Monitor how this capital infusion impacts Kopran Limited's consolidated financial performance in the coming quarters.
Kopran Ltd to Merge Kopran Laboratories; Promoter Stake to Increase to 55.33%
Kopran Limited has convened a meeting of equity shareholders on June 3, 2026, to approve the merger of Kopran Laboratories Limited into the company. Following the implementation of the scheme, the promoter group's shareholding will increase significantly from 44.43% to 55.33%. Conversely, public shareholding will decrease from 55.57% to 44.67%. The company claims the impact on the value of public holdings is nil, as the merger involves the transfer of all assets and liabilities from the transferor company.
Key Highlights
Amalgamation of Kopran Laboratories Limited into Kopran Limited as per NCLT directions.
Promoter shareholding to increase by 10.90% to a total of 55.33% post-merger.
Public shareholding to be diluted from 55.57% to 44.67% following the scheme.
Shareholders meeting scheduled for June 3, 2026, with e-voting starting May 27, 2026.
Valuation reports provided by Ernst & Young and fairness opinion by Saffron Capital Advisors.
👀 What to Watch
Investors should carefully review the valuation report and share exchange ratio to ensure the merger is priced fairly given the 10.90% increase in promoter stake. Monitor the post-merger operational synergies and debt levels of the combined entity.
Kopran Ltd Schedules NCLT-Convened Meeting on June 3, 2026, for Merger Approval
Kopran Limited has announced a court-convened meeting on June 03, 2026, to seek approval for the merger of Kopran Laboratories Limited into itself. This follows an NCLT Mumbai Bench order dated April 09, 2026, regarding the scheme of amalgamation by absorption. Separate meetings for equity shareholders, secured creditors, and unsecured creditors will be held throughout the day via video conferencing. The consolidation is part of a corporate restructuring aimed at streamlining group operations under Sections 230-232 of the Companies Act.
Key Highlights
NCLT-directed meetings for Kopran Ltd and Kopran Laboratories Ltd scheduled for June 03, 2026
The scheme involves the merger by absorption of Kopran Laboratories Limited into Kopran Limited
Equity shareholders of Kopran Limited are scheduled to meet at 10:00 AM IST on the meeting date
Notices and explanatory statements are being dispatched to all stakeholders as of April 30, 2026
👀 What to Watch
Shareholders should review the merger's explanatory statement on the company website and participate in the voting process on June 3. This consolidation is generally viewed as a positive step toward corporate simplification and operational synergy.
Kopran Ltd Schedules June 3 Meetings for Merger with Kopran Laboratories Ltd
Kopran Limited is proceeding with the merger of Kopran Laboratories Limited (Transferor) into itself (Transferee) following an NCLT Mumbai Bench order dated April 9, 2026. The company has scheduled separate meetings for equity shareholders, secured creditors, and unsecured creditors on June 3, 2026, to seek approval for the Scheme of Amalgamation. This merger by absorption is a significant corporate restructuring aimed at consolidating the group's laboratory and pharmaceutical operations. Investors should track the voting outcomes of these meetings as they are a critical step toward final regulatory approval.
Key Highlights
NCLT Mumbai Bench order dated April 9, 2026, mandates convening stakeholder meetings.
Equity shareholder meeting for Kopran Limited is scheduled for June 3, 2026, at 10:00 AM IST.
Secured and Unsecured creditor meetings for the listed entity are set for 11:30 AM and 1:00 PM on the same day.
The scheme involves the complete merger by absorption of Kopran Laboratories Limited into Kopran Limited.
Meetings will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
👀 What to Watch
Investors should monitor the voting results from the June 3 meetings to ensure stakeholder alignment on the merger. Review the scheme details on the company's website to understand the impact on share capital and potential operational synergies.
Kopran Receives NCLT Order to Convene Meetings for Merger with Kopran Laboratories
Kopran Limited has received a significant regulatory update regarding its proposed merger with Kopran Laboratories Limited. The National Company Law Tribunal (NCLT), Mumbai Bench, issued an order on April 09, 2026, directing the company to hold meetings for its equity shareholders and creditors. This merger, first announced in March 2025, aims to consolidate the transferor company into the listed entity. This procedural step is a critical milestone toward obtaining final legal approval for the amalgamation.
Key Highlights
NCLT Mumbai Bench issued a direction order on April 09, 2026, for the merger process.
The scheme involves the merger by absorption of Kopran Laboratories Limited into Kopran Limited.
Mandatory meetings must be convened for Equity Shareholders, Secured Creditors, and Unsecured Creditors.
The merger process was originally initiated and informed to exchanges on March 20, 2025.
The consolidation is being executed under Sections 230 to 232 of the Companies Act, 2013.
👀 What to Watch
Investors should monitor the outcome of the upcoming shareholder and creditor meetings as a 'Yes' vote is required to proceed. The merger is likely to simplify the corporate structure and potentially improve operational synergies.
Kopran Receives NSE 'No Objection' for Merger with Kopran Laboratories
Kopran Limited has received a 'No Objection' observation letter from the National Stock Exchange (NSE) on February 27, 2026, regarding its proposed merger with Kopran Laboratories Limited. This follows the initial board approval from March 20, 2025, and allows the company to proceed with filing the scheme before the NCLT. The company is now required to provide detailed disclosures to shareholders, including a 3-year financial track record (Revenue, PAT, EBITDA) and the impact on promoter shareholding. The merger aims to consolidate operations, though the final scheme remains subject to NCLT and other regulatory approvals.
Key Highlights
Received NSE 'No Objection' on February 27, 2026, for the merger of Kopran Laboratories into Kopran Limited.
The observation letter is valid for 6 months, requiring the scheme to be submitted to the NCLT by late August 2026.
Mandatory disclosure of 3-year audited financials (Revenue, PAT, EBITDA) for both entities is required for shareholder approval.
Company must prominently disclose any increase in promoter shareholding and the specific rationale for the swap ratio.
The scheme involves the transfer of all liabilities from the unlisted Transferor Company to the listed Transferee Company.
👀 What to Watch
Investors should review the upcoming shareholder notice for the specific swap ratio and the impact on promoter equity dilution. Monitor the NCLT approval process as the next major milestone for the consolidation.
Kopran Receives BSE 'No Adverse Observation' for Merger with Kopran Laboratories
Kopran Limited has received a 'no adverse observation' letter from BSE Limited regarding its proposed merger with Kopran Laboratories Limited. This regulatory milestone follows the initial board approval granted on March 20, 2025. The company is now authorized to proceed with filing the scheme before the National Company Law Tribunal (NCLT) within the next six months. The merger remains subject to further approvals from the NCLT, shareholders, and other regulatory bodies.
Key Highlights
BSE issued the 'no adverse observation' letter on February 26, 2026, for the Scheme of Amalgamation.
The merger involves the absorption of Kopran Laboratories Limited (Transferor) into Kopran Limited (Transferee).
The observation letter is valid for six months, during which the company must submit the scheme to the NCLT.
SEBI has mandated detailed disclosures in the shareholder notice, including a cost-benefit analysis and changes in promoter shareholding.
The company must ensure that financial data used for the valuation report is not more than six months old at the time of filing.
👀 What to Watch
Investors should monitor the upcoming NCLT filing and review the detailed explanatory statement for the swap ratio and potential synergy benefits. The stock may see positive sentiment as the consolidation process moves toward the final legal stages.
Kopran Limited Reports Cyber-attack on Server Data at Khopoli Factory
Kopran Limited has disclosed a cybersecurity incident involving unauthorized access to its computer server data at the Khopoli factory. The breach was identified on February 20, 2026, at approximately 3:50 p.m., prompting immediate restrictive actions by the company. Currently, Kopran is working with external cybersecurity experts to conduct a root cause analysis and assess any potential data or operational impact. While the company has taken steps to secure its systems, the full extent of the breach and its financial implications remain under investigation.
Key Highlights
Unauthorized access to computer server data detected at the Khopoli factory on February 20, 2026
Incident officially reported to the Compliance Officer at 3:50 p.m. on the same day
Immediate measures implemented to restrict further unauthorized access to the company's servers
Cybersecurity experts engaged for a thorough impact assessment and root cause analysis
👀 What to Watch
Investors should monitor subsequent filings for updates on data recovery and potential operational disruptions. Maintain a cautious stance until the company confirms no sensitive intellectual property or financial data was compromised.
Kopran Q3 Revenue Rises 17% YoY to ₹194 Cr; PAT Dips 10% to ₹9.34 Cr
Kopran Limited reported a 16.8% YoY increase in consolidated revenue from operations to ₹194.28 crore for the quarter ended December 31, 2025. Despite the revenue growth, consolidated net profit declined by 10.1% YoY to ₹9.34 crore, down from ₹10.40 crore in the same quarter last year. On a sequential basis, the company returned to profitability after reporting a net loss of ₹9.92 crore in the previous quarter (Q2 FY26). For the nine-month period, net profit remains significantly lower at ₹6.87 crore compared to ₹28.87 crore in the previous year.
Key Highlights
Consolidated Revenue from Operations grew 16.8% YoY to ₹194.28 crore in Q3 FY26.
Consolidated Net Profit for the quarter stood at ₹9.34 crore, a 10.1% decline from ₹10.40 crore in Q3 FY25.
The company achieved a significant sequential turnaround from a net loss of ₹9.92 crore in Q2 FY26.
Nine-month (9M FY26) consolidated PAT dropped sharply to ₹6.87 crore from ₹28.87 crore in 9M FY25.
Basic EPS for the quarter was ₹1.93, compared to ₹2.16 in the corresponding quarter of the previous year.
👀 What to Watch
Investors should note the sequential turnaround from a loss in Q2, but remain cautious due to the significant year-on-year decline in nine-month cumulative profitability. Monitor the company's ability to sustain this recovery and manage operating costs in the upcoming quarters.
Kopran Q3 FY26 Net Profit Recovers to ₹9.34 Cr; Revenue Up 17% YoY to ₹194.28 Cr
Kopran Limited reported a strong sequential recovery in Q3 FY26, with revenue reaching ₹194.28 crore, a 64.7% increase over Q2 FY26. Net profit returned to the black at ₹9.34 crore after a loss of ₹9.92 crore in the previous quarter, though it remains slightly lower than the ₹10.40 crore earned in Q3 FY25. EBITDA margins saw a significant rebound to 10.42% from a low of 2.51% in Q2. The company's revenue was well-balanced between its API (₹100.05 crore) and Formulations (₹92.31 crore) segments, with a heavy focus on exports.
Key Highlights
Revenue from operations grew 16.8% YoY to ₹194.28 crore and 64.7% QoQ.
Net Profit stood at ₹9.34 crore, recovering from a net loss of ₹9.92 crore in Q2 FY26.
EBITDA margin improved significantly to 10.42% compared to 2.51% in the preceding quarter.
API segment revenue reached ₹100.05 crore, with exports contributing 67% of the total API sales.
Formulations segment contributed ₹92.31 crore, with Penicillin-based products accounting for 59% of the mix.
👀 What to Watch
Investors should monitor the sustainability of the margin recovery and the progress of the new API facility at Panoli, Gujarat. The sharp sequential turnaround suggests operational issues from the previous quarter have been addressed.
Kopran Q3 Results: Revenue Grows 17% YoY to ₹194 Cr, PAT at ₹9.3 Cr with Strong QoQ Turnaround
Kopran Limited reported a consolidated revenue of ₹194.28 crore for Q3 FY26, a 16.8% increase compared to ₹166.24 crore in the same quarter last year. The company achieved a significant sequential turnaround, posting a PAT of ₹9.34 crore compared to a loss of ₹9.92 crore in Q2 FY26. However, on a year-on-year basis, PAT declined by approximately 10% from ₹10.40 crore. The nine-month performance remains weak, with cumulative PAT falling to ₹6.87 crore from ₹28.87 crore in the previous year, primarily due to higher expenses and forex losses earlier in the fiscal year.
Key Highlights
Consolidated Revenue from Operations rose 16.8% YoY to ₹19,427.98 Lakhs.
Achieved a sharp QoQ turnaround with a PAT of ₹933.96 Lakhs versus a loss of ₹992.32 Lakhs in the previous quarter.
9M FY26 PAT stands at ₹686.57 Lakhs, a significant drop from ₹2,887.46 Lakhs in 9M FY25.
Foreign Exchange Loss of ₹247.22 Lakhs was recorded in the consolidated results for the quarter.
Consolidated Basic EPS for the quarter stood at ₹1.93 compared to ₹2.16 in the year-ago period.
👀 What to Watch
Investors should focus on the company's ability to maintain this sequential recovery in margins and revenue. While the QoQ turnaround is positive, the sharp decline in nine-month cumulative profits suggests long-term cost pressures that warrant a cautious approach.
GST Authorities Conduct Search at Kopran's Mumbai and Raigad Facilities
Maharashtra State GST authorities initiated a search at Kopran Limited's registered office in Mumbai and its manufacturing facilities in Khopoli, Raigad on January 21, 2026. The search was conducted under Section 67 of the Maharashtra Goods and Services Tax Act, 2017. While the search is ongoing, the company has stated that normal operations remain unaffected and no specific allegations of violations have been shared by the officials yet. There is currently no quantifiable financial impact reported, but the situation warrants monitoring for potential tax liabilities or penalties.
Key Highlights
Search initiated by Deputy Commissioner of State Tax, SGST (Maharashtra) on January 21, 2026.
Action taken under Section 67 of the Maharashtra Goods and Services Tax Act, 2017.
Locations involved include the Mumbai registered office and Khopoli (Raigad) manufacturing works.
Company reports no impact on normal operations of factories or offices during the search process.
No specific violation details or financial implications have been communicated by authorities as of the announcement.
👀 What to Watch
Investors should monitor further disclosures regarding the outcome of the GST search to assess any potential tax demands or penalties. Maintain a cautious stance until the company clarifies the nature of the alleged contraventions.
CRISIL Reaffirms Kopran's Ratings at BBB+/A2; Placed on Watch with Developing Implications
CRISIL has reaffirmed the credit ratings for Kopran Limited and its subsidiary, Kopran Research Laboratories Limited, covering total bank facilities of Rs. 194.06 crore. The long-term rating is maintained at CRISIL BBB+ and the short-term rating at CRISIL A2. Notably, the ratings have been placed on 'Rating Watch with Developing Implications,' suggesting potential volatility in the credit profile. This status will remain in effect until March 31, 2026, pending further developments in the company's financial or operational standing.
Key Highlights
CRISIL reaffirmed Long-Term rating at BBB+ and Short-Term rating at A2 for the group.
Kopran Limited's total bank loan facilities rated amount to Rs. 69.31 Crore.
Subsidiary Kopran Research Laboratories Limited's facilities rated at Rs. 124.75 Crore.
All ratings placed on 'Rating Watch with Developing Implications' status.
The current ratings are valid through the period ending March 31, 2026.
👀 What to Watch
Investors should monitor the company for any corporate announcements or financial shifts that could resolve the 'Developing Implications' status. While the reaffirmation shows current stability, the watch status indicates potential for a rating change in the near future.
